Trial Profile
A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2016
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Carboplatin
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 01 Mar 2013 Actual end date Jun 2010 added as reported by ClinicalTrials.gov.
- 03 Mar 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 03 Mar 2011 Planned end date changed from 1 Sep 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.